Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth

• Published in: Signal transduction and targeted therapy Vol. 5; no. 1; p. 214
• Main Authors: Yao, Nan, Wang, Chen-Ran, Liu, Ming-Qun, Li, Ying-Jie, Chen, Wei-Min, Li, Zheng-Qiu, Qi, Qi, Lu, Jin-Jian, Fan, Chun-Lin, Chen, Min-Feng, Qi, Ming, Li, Xiao-Bo, Hong, Jian, Zhang, Dong-Mei, Ye, Wen-Cai
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 09.10.2020
• Subjects: 631/67/1059/153; 692/699/67/1612; Cancer Research; Cell Biology; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Pathology

Epidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy. EGFR tyrosine kinase inhibitors (TKIs) have been canonically used in NSCLC treatment. However, prevalent innate a...